Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene Chapman

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacology|May 16, 2019
β<sub>2</sub> -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical StudiesMohamed H Shahin, Nihal El Rouby, Daniela J Conrado, et al.
Kidney International|September 14, 2020
Mineral bone disease in autosomal dominant polycystic kidney diseaseBerenice Gitomer, Renata Pereira, Isidro B Salusky, et al.
American Journal of Nephrology|August 12, 2016
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration DefinitionsMichael V Rocco, Arlene Chapman, Glenn M Chertow, et al.
Pharmacotherapy|September 10, 2014
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazideMariellen J Moore, Yan Gong, Wei Hou, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 15, 2020
Advancing Nephrology: Division Leaders Advise ASNGregory L Braden, Arlene Chapman, David H Ellison, et al.
Metabolomics : Official Journal of the Metabolomic Society|February 21, 2017
Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenololLiming Weng, Yan Gong, Jeffrey Culver, et al.
Circulation. Cardiovascular Genetics|March 15, 2014
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?Rhonda M Cooper-Dehoff, Wei Hou, Liming Weng, et al.
Plos One|May 27, 2021
Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic reviewPatrizia Natale, Elyssa Hannan, Bénédicte Sautenet, et al.
Kidney International Reports|February 24, 2025
Validating the SONG-PKD Pain Instrument, a Core Outcome Measure for Pain in ADPKDRosanna Cazzolli, Angela Ju, Patrizia Natale, et al.
Trials|November 25, 2017
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney diseaseYeoungjee Cho, Benedicte Sautenet, Gopala Rangan, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacology|May 16, 2019
β<sub>2</sub> -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical StudiesMohamed H Shahin, Nihal El Rouby, Daniela J Conrado, et al.
Kidney International|September 14, 2020
Mineral bone disease in autosomal dominant polycystic kidney diseaseBerenice Gitomer, Renata Pereira, Isidro B Salusky, et al.
American Journal of Nephrology|August 12, 2016
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration DefinitionsMichael V Rocco, Arlene Chapman, Glenn M Chertow, et al.
Pharmacotherapy|September 10, 2014
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazideMariellen J Moore, Yan Gong, Wei Hou, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 15, 2020
Advancing Nephrology: Division Leaders Advise ASNGregory L Braden, Arlene Chapman, David H Ellison, et al.
Metabolomics : Official Journal of the Metabolomic Society|February 21, 2017
Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenololLiming Weng, Yan Gong, Jeffrey Culver, et al.
Circulation. Cardiovascular Genetics|March 15, 2014
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?Rhonda M Cooper-Dehoff, Wei Hou, Liming Weng, et al.
Plos One|May 27, 2021
Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic reviewPatrizia Natale, Elyssa Hannan, Bénédicte Sautenet, et al.
Kidney International Reports|February 24, 2025
Validating the SONG-PKD Pain Instrument, a Core Outcome Measure for Pain in ADPKDRosanna Cazzolli, Angela Ju, Patrizia Natale, et al.
Trials|November 25, 2017
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney diseaseYeoungjee Cho, Benedicte Sautenet, Gopala Rangan, et al.
Pageof 5